Literature DB >> 12070056

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

Demosthenes Bouros1, Athol U Wells, Andrew G Nicholson, Thomas V Colby, Vlasis Polychronopoulos, Panos Pantelidis, Patricia L Haslam, Dimitris A Vassilakis, Carol M Black, Roland M du Bois.   

Abstract

Fibrosing alveolitis associated with systemic sclerosis (FASSc) has a better prognosis than idiopathic pulmonary fibrosis. In view of recent reports that idiopathic nonspecific interstitial pneumonia (NSIP) has a better prognosis than idiopathic usual interstitial pneumonia (UIP), we classified histologic appearances of surgical lung biopsies performed in 80 patients with FASSc. NSIP (n = 62, 77.5%), subcategorized as cellular NSIP (n = 15) and fibrotic NSIP (n = 47) was much more prevalent than UIP (n = 6), end-stage lung disease (ESL, n = 6), or other patterns (n = 6). There were 25 deaths (NSIP 16/62, 26%; UIP/ESL 6/12, 50%). Five-year survival differed little between NSIP (91%) and UIP/ESL (82%); mortality was associated with lower initial carbon monoxide diffusing capacity (DL(CO)) and FVC levels (p = 0.004 and p = 0.007, respectively). Survival and serial FVC and DL(CO) trends did not differ between cellular and fibrotic NSIP. Increased mortality in NSIP was associated with lower initial DL(CO) levels (p = 0.04), higher BAL eosinophil levels (p = 0.03), and deterioration in DL(CO) levels during the next 3 years (p < 0.005). We conclude that NSIP is the histopathologic pattern in most patients with FASSc. However, outcome is linked more strongly to disease severity at presentation and serial DL(CO) trends than to histopathologic findings.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070056     DOI: 10.1164/rccm.2106012

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  153 in total

1.  Cyclophosphamide responsive interstitial lung disease in "overlap syndrome": a clinical pathology conference held by the division of rheumatology at the hospital for special surgery.

Authors:  Elizabeth Schulman; Kun Chen; Gregory Saboeiro; Abraham Sanders; Kyriakos Kirou; Robert F Spiera; Anne R Bass; Doruk Erkan
Journal:  HSS J       Date:  2010-10-26

2.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

3.  Lower-lobe shrinkage relative to total lung volume in collagen vascular diseases.

Authors:  M Watanabe; T Igishi; N Burioka; J Kurai; Y Fukuoka; K Kato; A Yamasaki; Y Hasegawa; R Okazaki; E Shimizu
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

Review 4.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

5.  Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement.

Authors:  Noha A Azab; Hanaa M Rady; Samar A Marzouk
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

Review 6.  Interstitial lung disease in scleroderma.

Authors:  Sara R Schoenfeld; Flavia V Castelino
Journal:  Rheum Dis Clin North Am       Date:  2015-02-26       Impact factor: 2.670

Review 7.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

8.  Treating CTDs related fibrotic ILDs by immunosuppressants: "facts and faults".

Authors:  Spyros A Papiris; Konstantinos Kagouridis; Georgia Papadaki; Likurgos Kolilekas; Effrosyni D Manali
Journal:  Lung       Date:  2013-11-12       Impact factor: 2.584

Review 9.  Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Authors:  Karen Au; Dinesh Khanna; Philip J Clements; Daniel E Furst; Donald P Tashkin
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 10.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.